What's New
New classes of drugs fully funded from 1st Oct 2018: vildagliptin and sacubitril/valsartanOctober 3, 2018
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved for the treatment of type 2 diabetes. See BPAC article for further information. Sacubitril/valsartan is approved for the treatment of symptomatic chronic heart failure with LVEF ≤40%. Sacubitril is a neprilysin inhibitor (inhibits breakdown of natriuretic peptides increasing diuresis, natriuresis, and vasodilation) and valsartan is an angiotensin-2 […]